<p>Reliant Investment Management LLC 在最近向證券交易委員會（SEC）提交的 13F 文件中披露，其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的股份在第二季度增加了 7.0%。該公司在本季度額外購買了 860 股後，持有該醫療研究公司 13,196 股股票。賽默飛世爾約佔 Reliant Investment Management LLC 投資組合的 2.3%，成為其第 25 大持倉。根據其最近向證券交易委員會（SEC）提交的文件，Reliant Investment Management LLC 在賽默飛世爾的持股價值為 5,350,000 美元。</p>
<ul>
<li>現金流關注：賽默飛世爾、能源轉移和網易</li>
</ul>
<p>其他幾家對沖基金和機構投資者也調整了對該股票的持有。Revolve Wealth Partners LLC 在第四季度將其在賽默飛世爾的股份增加了 4.2%。Revolve Wealth Partners LLC 目前持有 491 股該醫療研究公司的股票，價值 255,000 美元，此前在該期間內額外購買了 20 股。Lafayette Investments Inc. 在第二季度將其在賽默飛世爾的股份增加了 2.4%。Lafayette Investments Inc. 目前持有 927 股該醫療研究公司的股票，價值 376,000 美元，此前在該期間內額外購買了 22 股。Root Financial Partners LLC 在第一季度將其在賽默飛世爾的股份增加了 5.0%。Root Financial Partners LLC 目前持有 506 股該醫療研究公司的股票，價值 252,000 美元，此前在該期間內額外購買了 24 股。Rossmore Private Capital 在第一季度將其在賽默飛世爾的股份增加了 0.5%。Rossmore Private Capital 目前持有 4,652 股該醫療研究公司的股票，價值 2,315,000 美元，此前在該期間內額外購買了 24 股。最後，FARMERS &amp; MERCHANTS TRUST Co OF LONG BEACH 在第二季度將其在賽默飛世爾的股份增加了 3.1%。FARMERS &amp; MERCHANTS TRUST Co OF LONG BEACH 目前持有 803 股該醫療研究公司的股票，價值 326,000 美元，此前在該期間內額外購買了 24 股。機構投資者持有該公司 89.23% 的股票。</p>
<h2>賽默飛世爾股票上漲 1.9%</h2>
<p>NYSE:TMO 週四開盤價為 568.42 美元。賽默飛世爾的 1 年最低價為 385.46 美元，1 年最高價為 610.97 美元。該公司的流動比率為 1.93，速動比率為 1.50，債務股本比率為 0.65。該股票的市值為 2146.4 億美元，市盈率為 32.88，PEG 比率為 3.22，貝塔值為 0.77。該股票的 50 日移動平均價格為 500.65 美元，200 日移動平均價格為 451.30 美元。</p>
<ul>
<li>安捷倫科技受益於對持久化學品的打擊</li>
</ul>
<p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近於 10 月 22 日發佈了季度財報。該醫療研究公司報告本季度每股收益為 5.79 美元，超出分析師一致預期的 5.50 美元，超出幅度為 0.29 美元。該公司本季度的收入為 111.2 億美元，而分析師預期為 109 億美元。賽默飛世爾的股本回報率為 16.82%，淨利潤率為 15.24%。與去年同期相比，該公司的季度收入增長了 4.9%。在去年同期，該公司每股收益為 5.28 美元。賽默飛世爾已將其 2025 財年的指引設定為每股收益 22.600-22.860 美元。整體來看，股票分析師預計賽默飛世爾在當前年度將發佈每股收益 23.28 美元。</p>
<h2>賽默飛世爾的內部買賣</h2>
<p>在其他賽默飛世爾的新聞中，執行副總裁 Gianluca Pettiti 於 7 月 25 日星期五出售了 400 股賽默飛世爾的股票。該股票以平均價格 479.98 美元出售，總價值為 191,992.00 美元。交易完成後，該執行副總裁直接持有 22,367 股公司的股票，價值 10,735,712.66 美元。此次交易使其持股減少了 1.76%。該出售在向證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席會計官 Joseph R. Holmes 於 8 月 29 日星期五出售了 385 股公司的股票。該股票以平均價格 492.63 美元出售，總價值為 189,662.55 美元。出售後，首席會計官持有 2,319 股公司的股票，價值 1,142,408.97 美元。此次交易使其持股減少了 14.24%。該出售的披露信息可在此處找到。在過去 90 天內，內部人士已出售價值 14,182,963 美元的 30,066 股公司股票。公司內部人士持有公司股票的 0.33%。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>S&amp;P 500 中增長最快的 4 大股息：買入、賣出還是持有？</li>
</ul>
<p>多家券商對 Thermo Fisher Scientific 發佈了報告。摩根大通將 Thermo Fisher Scientific 的目標價從 600.00 美元上調至 650.00 美元，並在 10 月 9 日的研究報告中給予該公司 “增持” 評級。加拿大皇家銀行在 9 月 2 日的研究報告中設定了 Thermo Fisher Scientific 的目標價為 561.00 美元，並給予該公司 “跑贏大盤” 評級。羅伯特·W·貝爾德將 Thermo Fisher Scientific 的目標價從 553.00 美元上調至 567.00 美元，並在 7 月 24 日的研究報告中給予該公司 “跑贏大盤” 評級。巴克萊將 Thermo Fisher Scientific 的目標價從 550.00 美元上調至 585.00 美元，並在 10 月 2 日的研究報告中給予該公司 “增持” 評級。最後，雷蒙德·詹姆斯金融在 7 月 24 日的研究報告中重申了 “跑贏大盤” 評級，並將 Thermo Fisher Scientific 的目標價設定為 535.00 美元（之前為 525.00 美元）。十六位研究分析師對該股票給予了買入評級，五位分析師對該公司的股票給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 582.16 美元。</p>
<p><strong>獲取我們關於 Thermo Fisher Scientific 的最新報告</strong></p>
<h2>Thermo Fisher Scientific 公司簡介</h2>
<p>(免費報告)</p>
<p>Thermo Fisher Scientific Inc 在北美、歐洲、亞太地區及國際上提供生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務。該公司的生命科學解決方案部門為生物和醫學研究、藥物和疫苗的發現與生產，以及感染和疾病的診斷提供試劑、儀器和耗材；解決方案包括生物科學、遺傳科學和生物生產，服務於製藥、生物技術、農業、臨牀、醫療保健、學術和政府市場。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Thermo Fisher Scientific</li>
<li>WallStreetBets 是什麼，它們正在關注哪些股票？</li>
<li>你需要了解的突破性動量股票</li>
<li>頂級生物技術股票：探索創新機會</li>
<li>Quanta Services：AI 數據中心推動的支柱</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>Archer 最近一系列勝利標誌着增長的新階段</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Thermo Fisher Scientific 嗎？</h2>
<p>在考慮 Thermo Fisher Scientific 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Thermo Fisher Scientific 並不在名單上。</p>
<p>雖然 Thermo Fisher Scientific 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

賽默飛世爾

<p>Reliant Investment Management LLC 在第二季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO）的持股增加了 7.0%，額外購買了 860 股，總持股量達到 13,196 股，價值為 535 萬美元。該股票佔 Reliant 投資組合的 2.3%。其他機構投資者也增加了他們的持股。賽默飛世爾的股票開盤價為 568.42 美元，市值為 2146.4 億美元。該公司報告了第三季度每股收益為 5.79 美元，超出預期，並將 2025 財年的指導目標設定在 22.600-22.860 美元每股收益</p>

<p>Reliant Investment Management LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,196 shares of the medical research company's stock after buying an additional 860 shares during the quarter. Thermo Fisher Scientific accounts for about 2.3% of Reliant Investment Management LLC's investment portfolio, making the stock its 25th largest position. Reliant Investment Management LLC's holdings in Thermo Fisher Scientific were worth $5,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Reliant Investment Management LLC 在最近向證券交易委員會（SEC）提交的 13F 文件中披露，其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的股份在第二季度增加了 7.0%。該公司在本季度額外購買了 860 股後，持有該醫療研究公司 13,196 股股票。賽默飛世爾約佔 Reliant Investment Management LLC 投資組合的 2.3%，成為其第 25 大持倉。根據其最近向證券交易委員會（SEC）提交的文件，Reliant Investment Management LLC 在賽默飛世爾的持股價值為 5,350,000 美元。</p>
</div><ul>
<li>Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase</li>
</ul>
<div class="lb-trans"><ul>
<li>現金流關注：賽默飛世爾、能源轉移和網易</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also modified their holdings of the stock. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Lafayette Investments Inc. lifted its position in shares of Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company's stock worth $376,000 after buying an additional 22 shares during the period. Root Financial Partners LLC lifted its position in shares of Thermo Fisher Scientific by 5.0% during the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock worth $252,000 after buying an additional 24 shares during the period. Rossmore Private Capital lifted its position in shares of Thermo Fisher Scientific by 0.5% during the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock worth $2,315,000 after buying an additional 24 shares during the period. Finally, FARMERS &amp; MERCHANTS TRUST Co OF LONG BEACH lifted its position in shares of Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS &amp; MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company's stock worth $326,000 after buying an additional 24 shares during the period. Institutional investors own 89.23% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者也調整了對該股票的持有。Revolve Wealth Partners LLC 在第四季度將其在賽默飛世爾的股份增加了 4.2%。Revolve Wealth Partners LLC 目前持有 491 股該醫療研究公司的股票，價值 255,000 美元，此前在該期間內額外購買了 20 股。Lafayette Investments Inc. 在第二季度將其在賽默飛世爾的股份增加了 2.4%。Lafayette Investments Inc. 目前持有 927 股該醫療研究公司的股票，價值 376,000 美元，此前在該期間內額外購買了 22 股。Root Financial Partners LLC 在第一季度將其在賽默飛世爾的股份增加了 5.0%。Root Financial Partners LLC 目前持有 506 股該醫療研究公司的股票，價值 252,000 美元，此前在該期間內額外購買了 24 股。Rossmore Private Capital 在第一季度將其在賽默飛世爾的股份增加了 0.5%。Rossmore Private Capital 目前持有 4,652 股該醫療研究公司的股票，價值 2,315,000 美元，此前在該期間內額外購買了 24 股。最後，FARMERS &amp; MERCHANTS TRUST Co OF LONG BEACH 在第二季度將其在賽默飛世爾的股份增加了 3.1%。FARMERS &amp; MERCHANTS TRUST Co OF LONG BEACH 目前持有 803 股該醫療研究公司的股票，價值 326,000 美元，此前在該期間內額外購買了 24 股。機構投資者持有該公司 89.23% 的股票。</p>
</div><h2>Thermo Fisher Scientific Stock Up 1.9%</h2>
<div class="lb-trans"><h2>賽默飛世爾股票上漲 1.9%</h2>
</div><p>NYSE:TMO opened at $568.42 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market cap of $214.64 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 3.22 and a beta of 0.77. The stock has a 50-day moving average price of $500.65 and a two-hundred day moving average price of $451.30.</p>
<div class="lb-trans"><p>NYSE:TMO 週四開盤價為 568.42 美元。賽默飛世爾的 1 年最低價為 385.46 美元，1 年最高價為 610.97 美元。該公司的流動比率為 1.93，速動比率為 1.50，債務股本比率為 0.65。該股票的市值為 2146.4 億美元，市盈率為 32.88，PEG 比率為 3.22，貝塔值為 0.77。該股票的 50 日移動平均價格為 500.65 美元，200 日移動平均價格為 451.30 美元。</p>
</div><ul>
<li>Agilent Technologies Thrives From the Forever Chemicals Crackdown</li>
</ul>
<div class="lb-trans"><ul>
<li>安捷倫科技受益於對持久化學品的打擊</li>
</ul>
</div><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts' consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.</p>
<div class="lb-trans"><p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近於 10 月 22 日發佈了季度財報。該醫療研究公司報告本季度每股收益為 5.79 美元，超出分析師一致預期的 5.50 美元，超出幅度為 0.29 美元。該公司本季度的收入為 111.2 億美元，而分析師預期為 109 億美元。賽默飛世爾的股本回報率為 16.82%，淨利潤率為 15.24%。與去年同期相比，該公司的季度收入增長了 4.9%。在去年同期，該公司每股收益為 5.28 美元。賽默飛世爾已將其 2025 財年的指引設定為每股收益 22.600-22.860 美元。整體來看，股票分析師預計賽默飛世爾在當前年度將發佈每股收益 23.28 美元。</p>
</div><h2>Insider Buying and Selling at Thermo Fisher Scientific</h2>
<div class="lb-trans"><h2>賽默飛世爾的內部買賣</h2>
</div><p>In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last 90 days. Company insiders own 0.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他賽默飛世爾的新聞中，執行副總裁 Gianluca Pettiti 於 7 月 25 日星期五出售了 400 股賽默飛世爾的股票。該股票以平均價格 479.98 美元出售，總價值為 191,992.00 美元。交易完成後，該執行副總裁直接持有 22,367 股公司的股票，價值 10,735,712.66 美元。此次交易使其持股減少了 1.76%。該出售在向證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席會計官 Joseph R. Holmes 於 8 月 29 日星期五出售了 385 股公司的股票。該股票以平均價格 492.63 美元出售，總價值為 189,662.55 美元。出售後，首席會計官持有 2,319 股公司的股票，價值 1,142,408.97 美元。此次交易使其持股減少了 14.24%。該出售的披露信息可在此處找到。在過去 90 天內，內部人士已出售價值 14,182,963 美元的 30,066 股公司股票。公司內部人士持有公司股票的 0.33%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>Top 4 Fastest Growing S&amp;P 500 Dividends: Buy, Sell, or Hold?</li>
</ul>
<div class="lb-trans"><ul>
<li>S&amp;P 500 中增長最快的 4 大股息：買入、賣出還是持有？</li>
</ul>
</div><p>Several brokerages have issued reports on TMO. JPMorgan Chase &amp; Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, October 9th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, September 2nd. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, July 24th. Barclays lifted their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, October 2nd. Finally, Raymond James Financial reiterated an &#34;outperform&#34; rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $582.16.</p>
<div class="lb-trans"><p>多家券商對 Thermo Fisher Scientific 發佈了報告。摩根大通將 Thermo Fisher Scientific 的目標價從 600.00 美元上調至 650.00 美元，並在 10 月 9 日的研究報告中給予該公司 “增持” 評級。加拿大皇家銀行在 9 月 2 日的研究報告中設定了 Thermo Fisher Scientific 的目標價為 561.00 美元，並給予該公司 “跑贏大盤” 評級。羅伯特·W·貝爾德將 Thermo Fisher Scientific 的目標價從 553.00 美元上調至 567.00 美元，並在 7 月 24 日的研究報告中給予該公司 “跑贏大盤” 評級。巴克萊將 Thermo Fisher Scientific 的目標價從 550.00 美元上調至 585.00 美元，並在 10 月 2 日的研究報告中給予該公司 “增持” 評級。最後，雷蒙德·詹姆斯金融在 7 月 24 日的研究報告中重申了 “跑贏大盤” 評級，並將 Thermo Fisher Scientific 的目標價設定為 535.00 美元（之前為 525.00 美元）。十六位研究分析師對該股票給予了買入評級，五位分析師對該公司的股票給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 582.16 美元。</p>
</div><p><strong>Get Our Latest Report on Thermo Fisher Scientific</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Thermo Fisher Scientific 的最新報告</strong></p>
</div><h2>Thermo Fisher Scientific Company Profile</h2>
<div class="lb-trans"><h2>Thermo Fisher Scientific 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</p>
<div class="lb-trans"><p>Thermo Fisher Scientific Inc 在北美、歐洲、亞太地區及國際上提供生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務。該公司的生命科學解決方案部門為生物和醫學研究、藥物和疫苗的發現與生產，以及感染和疾病的診斷提供試劑、儀器和耗材；解決方案包括生物科學、遺傳科學和生物生產，服務於製藥、生物技術、農業、臨牀、醫療保健、學術和政府市場。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Thermo Fisher Scientific</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Breakout Momentum Plays You Need to Know About</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Quanta Services: The Backbone of the AI Data Center Push</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Archer’s Recent String of Victories Signals a New Phase of Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Thermo Fisher Scientific</li>
<li>WallStreetBets 是什麼，它們正在關注哪些股票？</li>
<li>你需要了解的突破性動量股票</li>
<li>頂級生物技術股票：探索創新機會</li>
<li>Quanta Services：AI 數據中心推動的支柱</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>Archer 最近一系列勝利標誌着增長的新階段</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Thermo Fisher Scientific 嗎？</h2>
</div><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Thermo Fisher Scientific 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Thermo Fisher Scientific 並不在名單上。</p>
</div><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Thermo Fisher Scientific 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Reliant Investment Management LLC 購買了 860 股賽默飛世爾公司的股票$TMO